1. Abraham E., Reinhart K., Opal S., et al. OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003, 290:238-247.
2. Alejandria M.,Lansang MA., Dans L.,et al. Intravenous immunoglobulin for treting sepsis and septic shock. Cochrane Database Syst Rev 2002 (1):CD001090.
3. Angus D.C., Marrie T.J., Obrosky D.S., et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002; 166: 717-23.
4. Annane D. Corticosteroids for severe sepsis: an evidence- based guide for physicians. Ann Intensive Care 2011; 1: 7-13.
5. Annane D., Bellissant E., Bollaert P-E., et al. Corticosteroids in treatment severe sepsis and septic shock in adults. A systematic review. JAMA 2009; 301(22): 2362-2375.
6. Annane D., Sebille V., Bellisant E., et al. Effect of low doses of corticosteroids in septic schock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006; 34: 22-30.
7. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-871.
8. Barbera J.A., Iglesia H., Cabello et al. Inhaled nitric oxide reduce intrapulmonary shunt in acute severe pneumonia. Am J Respir Crit Care Med 2000; 161 (Suppl): A849.
9. Bo L., Wang F., Zhu J., et al. Granulocyte-colony stimulating factor(G-CSF) and Granulocytemacrophage colony stimulating factor(GM-CSF) for sepsis: meta-analysis. Crit Care 2011; 15: R58.
1 0.Bone R.C., Balk R.A., Cerra F.B. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM consensus conference committee. Chest 1992; 101: 1644-1655.
1 1.Bridges C.B., Coyne-Beasley T., on behalf of the Advisory Committee on Immunization Practices. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2014. Ann Intern Med 2014; 160: 190-197.
12 .Chalmers J.D., Singanayagam A., Murray M.P., et al. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008; 121: 1002-1007.
13 .Charles P.G.P., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47: 375-384.
14 .Cheng A.C., Stephens D.P., Currie B.J. Granulocyte-Colony Stimulating Factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 2007, (2): CD004400.
15 .Confalonieri M., Potena A., Carbone G., et al. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 1999; 160: 1585-1591.
16 .Cronin L., Cook D., Carlet J., et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23:1430-1439.
17 .Ehrchen J., Steimuller L., Barczyk K., et al. Glucocorticoids induce differentiation of specefically activated anti-inflammatory subtype of human monocytes. Blood 2007; 109(3): 1265-1274.
18 .Ewig S., Schafer H., Torres A. Severity assessment in community-acquired pneumonia. Eur Respir J 2000; 16: 1193-1201.
19 .Ewig S., Woodhead M., Torres A. Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med 2011; 37: 214-223.
20 .Fine M.J., Smith M.A., Carson C.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275:134-141.
21 .Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
22 .Haque K.N., Remo C., Bahakim H. Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clin Exp Immunol 1995; 101: 328-33.
23 . Huang T.-S., Shyu Y.-C., Chen H.-Y., et al. Effect of parenteral selenium supplementation in critically ill patients: a systematic review and meta-analysis. PLos One 2013; 8(1): e54431.
24 .Jolliet P., Abajo B., Pasquina P., et al. Non-invasive pressure support ventilation in severe community-acquired pneumonia. Intensive Care Med 2001; 27: 812- 821.
25 .Kellum J., Kong L., Fink M., et al. Undestanding the inflammatory cytokin response in pneumonia and sepsis. Arch Intern Med 2007; 167: 1655-1663.
26 . Kim D.-K., Poudel B. Tools to Detect Influenza Virus. Yonsei Med J 2013; 54(3): 560-566.
27 .Kopterides P., Falagas M. Statins for sepsis: a critical and update review. Clin Microbiol Inf 2009; 15: 325-334.
28 .Kozlov R., Dekhnich A., Edelstein M., et al. Summary of comparative in vitro ceftaroline activity against major bacterial pathogens in Russia (2008-2012): results of multicenter study (Cerberus study). Proceedings of IDWeek 2013, San Francisco, CA, US. 2-6 October 2013, Abstract # 713.
29 .Kreymann K.G., de Heer G., Nierhaus A., at al. Use polyclonal immunoglobulin as adjunctive therapy for severe sepsis and septic shock. Crit Care Med 2007; 35: 2677-2685.
30 .Laupland K., Rirpatrick A., Delaney A. Polyclonal immunoglobulin for treatment severe sepsis and septic shock in crically ill audults. A systematic review and meta-analysis. Crit Care Med 2007; 35: 2686-2692.
31 .Lim W.S., Baudouin S.V., George R.C., et al. British Thoracic Society guidelines for the management of community-acquired pneumonia in adults - update 2009. Thorax 2009; 64 (Suppl III): iii1-55.
32 .Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 37782.
33 .Mandell L.M., Wunderink R.G, Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007; 44 (Suppl 2): S27-72.